|
FDA Grants Permanent Hair Reduction Labeling for Tria Laser Hair Removal System
January 11, 2010
VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 Minutes
January 11, 2010
Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuron Subsidiary
December 21, 2009
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
December 18, 2009
LensAR Inc. to Present Data from Laser Cataract Surgery Clinical Trial at the Annual Meeting of the American Academy of Ophthalmology
October 13, 2009
TransEnterix Secures $55 Million in Financing
October 7, 2009
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
October 08, 2009
Allos Therapeutics' FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
September 25, 2009
Sirion Therapeutics Announces FDA Approval of Zirgan™ (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis
September 16, 2009
VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
September 9, 2009
Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules
June 17, 2009
MAP Pharmaceuticals Phase 3 Trial of LEVADEX™ Migraine Product Candidate Meets All Four Primary Endpoints
May 26, 2009
SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.
May 11, 2009
Tria Beauty Announces New and Improved Tria Laser Hair Removal System
February 24, 2009
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
February 23, 2009
AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide
December 19, 2008
Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate Study (OB-301)
December 11, 2008
TRIA Beauty wins as the Prestige Skin Care Breakthrough Product of the Year
December 11, 2008
Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia
December 9, 2008
Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology
December 6, 2008
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
October 26, 2008
CeNeRx BioPharma Completes $15 Million Series B Financing
October 17, 2008
Sirion Therapeutics Announces Positive Pivotal Uveitis Data For Durezol™
October 14, 2008
Allure Magazine Names Tria Laser a Beauty Breakthrough Product of 2008
September 17, 2008
Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX(TM) Phase IIb Study for Peyronie's Disease
September 17, 2008
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
August 6, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
July 14, 2008
Dynova Laboratories Brings OTC Healhcare Marketing Expertise To Natural Products Market, Acquires “Sinus Buster” Company
July, 2008
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX™ Meets Primary Endpoint With Statistical Significance (p
< 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
June 03, 2008
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
April 7, 2008
New Microfluidic Technology for Proteomic Research
April 1, 2008
Advion Acquires the Assets of its BioSystems Manufacturing Partner
March 12, 2008
Barrier Therapeutics Announces Top Management Succession Plan
January 25, 2008
CeNeRx BioPharma Announces Successful Completion of Phase 1 Clinical Program for Novel Antidepressant Agent Tyrima™
January 15, 2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
January 7, 2008
|
